Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label…
<!-- Name:DistributionId Value:8754966 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
ATGAA
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
PHILADELPHIA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel…
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
FDA Issues Deferred Action Letter on AT-GAA Regulatory Filing Due to the Inability to Conduct Required Manufacturing Site Inspection Prior to the PDUFA Action Date Company is Now…
European Medicines Agency Validates Amicus Therapeutics Marketing Authorization…
PHILADELPHIA, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the European Medicines Agency (EMA) validated the Marketing Authorization…